Trial Profile
The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Beraprost (Primary)
- Indications Diabetic nephropathies; Embolism and thrombosis; Peripheral arterial disorders
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 09 Jul 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 21 Feb 2013 New trial record